Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

201 projects found matching your search criteria :

  1. Searching for effective strategies to protect neuronal cells against hypoxia and ischemia: Identification of neuroprotec...

    Call: OPUS 16 , Panel: NZ7

    Principal investigator: prof. Małgorzata Kajta

    Instytut Farmakologii PAN

  2. The role of nitric oxide-dependent pathways in the procognitive effects of muscarinic and metabotropic glutamate recepto...

    Call: OPUS 17 , Panel: NZ7

    Principal investigator: dr hab. Joanna Monika Wierońska

    Instytut Farmakologii PAN

  3. Evaluation of molecular mechanisms of neuroprotective action of dental pulp stromal cells in an ex vivo organotypic mode...

    Call: PRELUDIUM 18 , Panel: NZ7

    Principal investigator: dr Natalia Helena Bryniarska-Kubiak

    Instytut Farmakologii PAN

  4. ROS-Scavenging Magnetic Nanozymes with Remote Activation for Alzheimer Disease

    Call: M-ERA.NET 3 Call 2023 , Panel: NZ5

    Principal investigator: dr hab. Anna Ludwika Haduch

    Instytut Farmakologii PAN

  5. Semaglutide and neurodevelopment: investigating risks arising from prenatal exposure to a widely popular drug for diabet...

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr hab. Agnieszka Wnuk

    Instytut Farmakologii PAN

  6. Mechanisms of Antidepressant Action of Psilocybin: The Role of 5-HT2B-5-HT1A Receptor Dimerization and GSK-3β Activation...

    Call: OPUS 27 , Panel: NZ7

    Principal investigator: dr hab. Agata Faron-Górecka

    Instytut Farmakologii PAN

  7. A new concept of inhibiting the progression of Alzheimer's disease based on the modification of the blood-brain barrier ...

    Call: OPUS 28 , Panel: NZ4

    Principal investigator: prof. Agnieszka Basta-Kaim

    Instytut Farmakologii PAN

  8. The impact of H3 histamine receptor modulation on oligodendrogenesis and neurogenesis: a new strategy for the treatment ...

    Call: PRELUDIUM 24 , Panel: NZ5

    Principal investigator: Maciej Degutis

    Instytut Farmakologii PAN

  9. Contribution of nitrergic transmission in the modulation of L-dopa activity in the rat 6-OHDA model of Parkinson's disea...

    Call: OPUS 1 , Panel: NZ4

    Principal investigator: dr hab. Elżbieta Kazimiera Lorenc-Koci

    Instytut Farmakologii PAN

  10. Znaczenie interakcji układu endokanabinoidowego i endowaniloidowego w leczeniu bólu przewlekłego - potencjał terapeutycz...

    Call: ETIUDA 3 , Panel: NZ7

    Principal investigator: Natalia Eleonora Małek

    Instytut Farmakologii PAN

  11. Altered interaction between NMDA receptor subunits and their scaffolding proteins as a critical step to control drug see...

    Call: OPUS 9 , Panel: NZ7

    Principal investigator: prof. Małgorzata Maria Filip

    Instytut Farmakologii PAN

  12. Simultaneous stimulation of muscarinic M4 receptor and selected receptors involved in the regulation of glutamate releas...

    Call: OPUS 9 , Panel: NZ7

    Principal investigator: dr hab. Joanna Monika Wierońska

    Instytut Farmakologii PAN

  13. Impact of selective modulators of estrogen and aryl hydrocarbon receptors on hypoxia/ischemia-induced neuronal cell dama...

    Call: PRELUDIUM 1 , Panel: NZ3

    Principal investigator: Joanna Rzemieniec

    Instytut Farmakologii PAN

  14. EFFECTS OF ADENOSINE A2A RECEPTOR LIGANDS ON BEHAVIORAL EFFECTS OF ABUSED DRUG (COCAINE) AND NATURAL REWARD (FOOD) USING...

    Call: PRELUDIUM 2 , Panel: NZ7

    Principal investigator: Karolina Agnieszka Wydra

    Instytut Farmakologii PAN

  15. Plasticity of glutamatergic synapses on dopamine neurons: the mechanism of habit formation.

    Call: HARMONIA 3 , Panel: NZ4

    Principal investigator: dr hab. Jan Manuel Rodriguez-Parkitna

    Instytut Farmakologii PAN

  16. Effects of restraint stress on properties of neurons and synaptic transmission in hypothalamic paraventricular nucleus o...

    Call: PRELUDIUM 4 , Panel: NZ4

    Principal investigator: Magdalena Joanna Kusek

    Instytut Farmakologii PAN

  17. Examine the importance of intracellular pathways in the action of opioids in microglial cells in vitro

    Call: PRELUDIUM 4 , Panel: NZ3

    Principal investigator: Katarzyna Popiołek-Barczyk

    Instytut Farmakologii PAN

  18. Neural mechanisms underlying pathology of motivation.

    Call: SONATA BIS 2 , Panel: NZ3

    Principal investigator: dr Jan Manuel Rodriguez-Parkitna

    Instytut Farmakologii PAN

  19. The effect of enriched environment on the epigenetic mechanism in neurodevelopmental model of schizophrenia.

    Call: PRELUDIUM 4 , Panel: NZ4

    Principal investigator: dr Ewelina Bator

    Instytut Farmakologii PAN

  20. Antidepressats as substances that increase the activity of risperidone, an atypical antipsychotic drug in animal models

    Call: PRELUDIUM 5 , Panel: NZ7

    Principal investigator: Katarzyna Karolina Kamińska

    Instytut Farmakologii PAN

  21. The influence of perinatal exposure to selective serotonin reuptake inhibitors on the structure and functions of mice do...

    Call: OPUS 14 , Panel: NZ4

    Principal investigator: prof. Grzegorz Władysław Hess

    Instytut Farmakologii PAN

  22. The role of selected metabotropic glutamate receptors in the mechanism of rapid antidepressant effect of RS-ketamine and...

    Call: OPUS 14 , Panel: NZ7

    Principal investigator: dr hab. Agnieszka Pałucha-Poniewiera

    Instytut Farmakologii PAN

  23. Rational design and evaluation of functionally biased opioid agonists

    Call: OPUS 16 , Panel: NZ7

    Principal investigator: prof. Ryszard Przewłocki

    Instytut Farmakologii PAN

  24. Ocena roli wybranych białek neuronalnych i mikroglejowych w patogenezie schizofrenii - badania w modelu zwierzęcym.

    Call: ETIUDA 7 , Panel: NZ4

    Principal investigator: Katarzyna Anna Chamera

    Instytut Farmakologii PAN

  25. Investigation of molecular mechanisms of rapid antidepressant action of NLX-101, a biased agonist of the 5-HT1A receptor...

    Call: OPUS 18 , Panel: NZ7

    Principal investigator: prof. Mariusz Papp

    Instytut Farmakologii PAN

  26. Functional dissection of three alpha(1)-adrenergic receptor subtypes in the effects of antidepressant drugs: exploitatio...

    Call: OPUS 9 , Panel: NZ7

    Principal investigator: prof. Irena Maria Nalepa

    Instytut Farmakologii PAN

  27. The role of the neuron-microglia CX3CL1-CX3CR1 and CD200-CD200R protein systems in molecular mechanisms of antipsychotic...

    Call: OPUS 10 , Panel: NZ7

    Principal investigator: prof. Agnieszka Basta-Kaim

    Instytut Farmakologii PAN

  28. Fingerprint Połączeń Podstrukturalnych - nowa metoda reprezentacji związków chemicznych

    Call: ETIUDA 4 , Panel: NZ2

    Principal investigator: Krzysztof Rataj

    Instytut Farmakologii PAN

  29. Maternal diet during gestation and nutrition as a risk factor for cocaine use disorder in offspring - preclinical behavi...

    Call: OPUS 11 , Panel: NZ4

    Principal investigator: prof. Małgorzata Maria Filip

    Instytut Farmakologii PAN

  30. Modulation of amygdala neural network activity by the 5-HT7 receptor

    Call: OPUS 11 , Panel: NZ4

    Principal investigator: prof. Krzysztof Tokarski

    Instytut Farmakologii PAN

  31. The role of synovial fibroblasts' activity in joint pain in osteoarthritis

    Call: OPUS 12 , Panel: NZ7

    Principal investigator: dr hab. Katarzyna Maria Starowicz-Bubak

    Instytut Farmakologii PAN

  32. Role of oxidative stress and ceramide in the pathogenesis of depression and in the mechanizm of action of antidepressant...

    Call: PRELUDIUM 12 , Panel: NZ5

    Principal investigator: Justyna Józefa Brodowicz

    Instytut Farmakologii PAN

  33. Pharmacological and optogenetic investigation of the mechanism of action of Deep Brain Stimulation of the ventromedial p...

    Call: OPUS 13 , Panel: NZ7

    Principal investigator: prof. Mariusz Papp

    Instytut Farmakologii PAN

  34. The role of endoplasmic reticulum stress in the pathomechanisms of early-life stress-induced dysfunction of the prefrona...

    Call: OPUS 13 , Panel: NZ7

    Principal investigator: dr hab. Agnieszka Chocyk

    Instytut Farmakologii PAN

  35. Impact of pharmacogenetic profiles on depression treatment outcomes

    Call: SONATINA 5 , Panel: NZ2

    Principal investigator: dr Małgorzata Maria Borczyk

    Instytut Farmakologii PAN

  36. New post-treatment strategy against stroke and perinatal asphyxia – a novel approach based on a selective activation of ...

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr hab. Agnieszka Wnuk

    Instytut Farmakologii PAN

  37. Enhancement of antidepressant therapy by combined administration of hyperforin and ketamine: behavioral and molecular st...

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Bartłomiej Pochwat

    Instytut Farmakologii PAN

  38. Genetics of GR-dependent behavioral traits in humans

    Call: OPUS 23 , Panel: NZ5

    Principal investigator: dr hab. Michał Korostyński

    Instytut Farmakologii PAN

  39. The developmental changes in the endogenous opioid system associated with altered sensitivity to reward during adolescen...

    Call: PRELUDIUM 21 , Panel: NZ4

    Principal investigator: Klaudia Weronika Misiołek

    Instytut Farmakologii PAN

  40. "I like to move it, move it" – molecular dynamics-driven optimization of ligand residence time as an opportunity to impr...

    Call: OPUS 25 , Panel: NZ7

    Principal investigator: dr hab. Sabina Marta Podlewska

    Instytut Farmakologii PAN

  41. Evaluation of histopathological changes in the rats tissues after acute and chronic administration of the compounds from...

    Call: PRELUDIUM 6 , Panel: NZ7

    Principal investigator: Edyta Dorota Możdżeń

    Instytut Farmakologii PAN

  42. Pessimism as cognitive biomarker of depression in animal model

    Call: OPUS 7 , Panel: NZ4

    Principal investigator: dr hab. Rafał Ryguła

    Instytut Farmakologii PAN

  43. Targeting peripheral cannabinoid receptors CB2 as a novel therapy to treat osteoarthritis

    Call: OPUS 7 , Panel: NZ7

    Principal investigator: dr hab. Katarzyna Maria Starowicz-Bubak

    Instytut Farmakologii PAN

  44. Molecular mechanism of unique action of clozapine in the context of GPCR.

    Call: OPUS 8 , Panel: NZ7

    Principal investigator: dr Agata Faron-Górecka

    Instytut Farmakologii PAN

  45. Wykorzystanie metod uczenia maszynowego w zadaniach komputerowo wspomaganego projektowania leków.

    Call: ETIUDA 3 , Panel: NZ2

    Principal investigator: Sabina Marta Podlewska

    Instytut Farmakologii PAN

  46. Modeling Progression of α-Synucleinopathy in Noradrenergic and Serotonergic Systems – Possible Link with Prodromal Sympt...

    Call: PRELUDIUM 23 , Panel: NZ4

    Principal investigator: Anna Hajam Alwani

    Instytut Farmakologii PAN

  47. Reinforcement sensitivity phenotypes as determinants of various motivational styles of alcohol drinking: craving for rew...

    Call: OPUS 28 , Panel: HS6

    Principal investigator: prof. Rafał Ryguła

    Instytut Farmakologii PAN

  48. Positioning the aryl hydrocarbon receptor (AhR) as a new target for pharmacotherapy of sporadic Alzheimer disease: verif...

    Call: OPUS 28 , Panel: NZ7

    Principal investigator: prof. Małgorzata Kajta

    Instytut Farmakologii PAN

  49. Design and Pharmacological Evaluation of Marine Alkaloid-Inspired 5-HT2A Receptor Ligands

    Call: PRELUDIUM 24 , Panel: NZ1

    Principal investigator: Szymon Kazimierz Kordylewski

    Instytut Farmakologii PAN

  50. Identification of cytochrome P450 isoenzymes involved in the metabolism of levomepromazine in the human

    Call: OPUS 1 , Panel: NZ4

    Principal investigator: dr hab. Jacek Wójcikowski

    Instytut Farmakologii PAN

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy